Beneficiary 7: TEVA

TEVA Pharmaceutical Industries Ltd. (TEVA)

Scientist in Charge: Bianca Avramovitch

Teva Pharmaceuticals was established at 1901 and since then gained 115 years of experience in GMP-manufacturing and marketing drugs all over the world. Today TEVA has a portfolio of more than 1,000 molecules, producing approximately 64 billion tablets and capsules a year at 66 manufacturing facilities. TEVA has the most extensive product portfolio in the industry, a powerful research and development expertise, and moreover an efficient, high-quality manufacturing on a global scale.

Although TEVA considered as the world’s leading provider of generic pharmaceuticals, has world-leading position in innovative treatments for different therapeutic areas; In 1996 TEVA’s first major new drug, Copaxone® for the treatment of Multiple Sclerosis (MS), was approved by the FDA. TEVA invests in a series of acquisitions that extend its global reach in the US and Europe. TEVA’s exceptional integration of generics and specialty R&D enables her to generate a robust pipeline of high-value medicines, with an emphasis on complex and branded generics.